These results suggest that the lack of NLRP6 inflammasome activity does not affect the degree of liver injury and steatosis during ALD, but slightly impairs inflammatory signaling and strongly reduces the extent of hepatic immune cell recruitment. The gene discussed is NLRP6; the disease is steatosis.